Why can't albumin binding give monthly dosing?

It is a shielding strategy with a practical ceiling around a week. Antibodies persist longer because FcRn actively retrieves them from degradation.

What is the neonatal Fc receptor?

A receptor that binds antibodies taken into cells and returns them to circulation rather than letting them be degraded — the basis of antibody persistence.

What is the downside of monthly dosing?

Reversibility. A long-acting compound cannot be cleared quickly by withholding the next dose if adverse effects appear.

GLP-1 & Incretin Science

How a Molecule Lasts a Month Instead of a Week

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

Weekly incretin dosing is achieved by binding albumin reversibly. Monthly dosing requires a different mechanism: conjugating the active peptides to a monoclonal antibody, which persists far longer because it is recycled by the neonatal Fc receptor rather than merely shielded.

Key facts

Weekly mechanism: Reversible albumin binding
Monthly mechanism: Antibody conjugation
Key receptor: Neonatal Fc receptor (FcRn)
Antibody persistence: Weeks, not hours
Example: Maridebart cafraglutide, once monthly
Phase 2 readout: NEJM, 4 September 2025

What albumin binding achieves and where it stops

A fatty acid attached to a peptide binds albumin reversibly, which prevents renal filtration and shields against proteases. That takes native GLP-1 from minutes to about a week for semaglutide. It is a shielding strategy — the peptide survives longer because it is hidden — and roughly a week is where that approach plateaus.

Why antibodies last so much longer

Not shielding but active rescue. The neonatal Fc receptor binds antibodies taken up into cells and returns them to circulation instead of allowing degradation. That recycling is why monoclonal antibodies persist for weeks — they are not merely evading clearance, they are being retrieved from it.

Research material referenced

Retatrutide 10mg — third-party HPLC tested

View — £59.99

The conjugate idea

Attach the pharmacologically active peptides to an antibody and they inherit its pharmacokinetics. Maridebart cafraglutide does this: a monoclonal antibody against the GIP receptor, with GLP-1 receptor agonist peptides conjugated through amino-acid linkers. The antibody is not a passive carrier — it is itself one of the two pharmacological actions — but it also supplies the duration.

Why monthly dosing is worth engineering for

Adherence to any chronic treatment declines with how often it must be taken, and a self-administered weekly injection is a recurring demand. Twelve administrations a year rather than fifty-two is a different proposition, particularly for a condition requiring indefinite treatment. Whether that translates into better real-world outcomes is a separate question from whether it is pharmacologically achievable.

What long duration costs

Control. A compound with a one-week half-life is largely cleared within a month of stopping; one dosed monthly is not. If adverse effects appear, they cannot be ended promptly by withholding the next dose. Long duration is a convenience benefit and a reversibility cost, and the two are inseparable.

Regulatory position

Maridebart cafraglutide is investigational and holds no marketing authorisation anywhere. Its Phase 3 programme is ongoing. Nothing supplied here is related to it or to any licensed weight-management medicine.

Quick reference

Strategy	Mechanism	Interval
Native GLP-1	None	Minutes
C16 palmitic (liraglutide)	Weak albumin binding	Daily
C18/C20 diacid	Strong albumin binding	Weekly
Antibody conjugate	FcRn recycling	Monthly

Extended research context

The GLP-1 & Incretin Science deep dive

Deep dive: the two routes to a bigger effect

Every compound trying to beat GLP-1 alone has taken one of two routes. The first adds more receptors from the same hormone family — GIP in tirzepatide, GIP and glucagon in retatrutide. The second adds a non-incretin satiety hormone, which in practice means amylin: CagriSema combines cagrilintide with semaglutide, and amycretin engages both receptors from one molecule. Both routes work, because they recruit signalling pathways that do not fully overlap. Neither has escaped the constraint that binds all of them, which is that gastrointestinal tolerability worsens as effect size grows.

Deep dive: why a percentage is not a result

The most-quoted numbers in this field are the least comparable. REDEFINE 1 reported 22.7% and 20.4% for the same compound in the same trial — the first among participants who adhered to treatment, the second across everyone randomised. TRIUMPH-1 reported 28.3% in an uncomplicated obesity population while TRIUMPH-3 reported up to 22.6% in adults with established cardiovascular disease, using the same compound. Before any two figures can be compared they have to match on estimand, population, duration, comparator and whether the number is placebo-adjusted. Most published comparisons match on none of them.

Deep dive: what happens after the trial stops

Every headline figure describes weight while treatment continues. The STEP-1 extension found that a year after semaglutide was stopped, participants had given back roughly two-thirds of what they lost, moving from 17.3% mean reduction to a net 5.6% — though average weight remained below baseline and nearly half stayed at least 5% down. Meta-analysis puts regain at around 0.8 kg per month. This is why maintenance studies such as TRIUMPH-6 matter more to the field's future than another two points of peak reduction.

Research applications

▸Comparing incretin and amylin compounds on a like-for-like basis
▸Interpreting estimands, thresholds and placebo-adjusted figures in trial reports
▸Tracking the obesity pipeline across sponsors and jurisdictions
▸Understanding receptor pharmacology behind GLP-1, GIP, glucagon and amylin
▸Distinguishing licensed medicines from investigational compounds

Handling checklist

✓Identify which estimand a quoted percentage comes from before citing it
✓Check the trial population and baseline BMI against the comparison you are making
✓Confirm the duration and whether the reduction curve had plateaued
✓Read discontinuation rates alongside efficacy figures
✓Verify every NCT identifier against ClinicalTrials.gov rather than secondary reporting

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Comparing headline percentages across different trials

Fix: Population, duration, estimand and comparator all differ; the numbers are not interchangeable.

✗ Quoting the larger of two figures from the same trial

Fix: Name the estimand. Efficacy and treatment-policy answer different questions.

✗ Treating peak reduction as a durable outcome

Fix: Substantial regain follows cessation across the class; peak figures describe a maintained state.

✗ Assuming an oral route means a weaker mechanism

Fix: Route and receptor count are independent. Orforglipron is weaker because it hits one receptor, not because it is a tablet.

✗ Reading investigational compounds as available treatments

Fix: Most of this pipeline holds no authorisation anywhere; mazdutide is approved only in China.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Why can't albumin binding give monthly dosing?: It is a shielding strategy with a practical ceiling around a week. Antibodies persist longer because FcRn actively retrieves them from degradation.
What is the neonatal Fc receptor?: A receptor that binds antibodies taken into cells and returns them to circulation rather than letting them be degraded — the basis of antibody persistence.
What is the downside of monthly dosing?: Reversibility. A long-acting compound cannot be cleared quickly by withholding the next dose if adverse effects appear.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More GLP-1 & Incretin Science articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum